A Continued Access protocol for eligible US subjects with Duchenne Muscular Dystrophy who previously participated in an approved drisapersen study

Principal Investigator: Kathryn Wagner

This is a single arm, open-label continued access protocol of drisapersen for the treatment of male subjects with DMD having dystrophin mutations correctable by drisapersen induced DMD Exon 51 skipping. The protocol is open only to subjects who completed GSK protocol DMD114876.